Glycorex Transplantation
Glycorex Transplantation AB specializes in innovative molecular-level nanotechnology that specifically removes antibodies in the blood, enabling revolutionary treatments in transplantation, autoimmune disease management, and blood treatment. The company’s solutions facilitate transplants across blood groups, increasing organ availability and improving patient outcomes. With a history of over 6,000 successful transplants since 2001, Glycorex is expanding into new applications including universal blood plasma and treatments for severe autoimmune diseases like rheumatoid arthritis. The company is committed to improving healthcare and saving lives through its advanced medical devices and therapies.
Industries
Nr. of Employees
small (1-50)
Glycorex Transplantation
Patents
Products
Immunoadsorption column for selective anti-A/B antibody removal (transplant desensitization)
Single‑use extracorporeal affinity column designed to selectively remove anti-A and anti-B antibodies from patient plasma to enable desensitization prior to or during organ and stem cell transplantation, while minimizing effects on other plasma proteins.
Immunoadsorption column for production of universal blood plasma (donor plasma processing)
Single‑use column variant for processing donated plasma to reduce anti-A/B antibody titers and produce low‑titer (universal) plasma suitable for transfusion regardless of recipient blood group; intended for use in blood banks and transfusion centers.
Immunoadsorption column for selective anti-A/B antibody removal (transplant desensitization)
Single‑use extracorporeal affinity column designed to selectively remove anti-A and anti-B antibodies from patient plasma to enable desensitization prior to or during organ and stem cell transplantation, while minimizing effects on other plasma proteins.
Immunoadsorption column for production of universal blood plasma (donor plasma processing)
Single‑use column variant for processing donated plasma to reduce anti-A/B antibody titers and produce low‑titer (universal) plasma suitable for transfusion regardless of recipient blood group; intended for use in blood banks and transfusion centers.
Services
Distribution and delivery of single‑use immunoadsorption columns and related consumables to transplant clinics, blood banks and transfusion centers, including regional distribution agreements.
Provision of clinical data, publications and practical guidance to support implementation of extracorporeal immunoadsorption in transplantation and transfusion workflows; collaboration with clinical research centers.
Distribution and delivery of single‑use immunoadsorption columns and related consumables to transplant clinics, blood banks and transfusion centers, including regional distribution agreements.
Provision of clinical data, publications and practical guidance to support implementation of extracorporeal immunoadsorption in transplantation and transfusion workflows; collaboration with clinical research centers.
Expertise Areas
- Extracorporeal immunoadsorption
- Transfusion medicine and blood component processing
- ABO-incompatible transplantation
- Clinical evidence generation and medical publications
Key Technologies
- Antigen-specific immunoadsorption
- Carbohydrate-based affinity ligands
- Extracorporeal plasma processing
- Immunoaffinity adsorption columns
News & Updates
Glycorex facilitated the first ABO-incompatible organ transplant in Morocco using Glycosorb® ABO.
The company has signed a distribution agreement in Greece to expand the use of Glycosorb® ABO in transplantation and transfusion.
Glycorex facilitated the first ABO-incompatible kidney transplant in Portugal.
Glycorex facilitated the first ABO-incompatible organ transplant in Morocco using Glycosorb® ABO.
The company has signed a distribution agreement in Greece to expand the use of Glycosorb® ABO in transplantation and transfusion.
Glycorex facilitated the first ABO-incompatible kidney transplant in Portugal.